ResearchMoz

Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends

GlobalData
Published Date » 2013-11-30
No. Of Pages » 107
   
 GlobalData's Pharmaceuticals Monthly Deals Analysis: October 2013 Partnerships, Licensing, Investments and M&A Trends report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2013 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
2.2.1 McKesson to Acquire Celesio for US$8.3 Billion 14
2.2.2 Bristol-Myers Squibb Completes Public Offering of Notes for US$1.5 Billion 16
2.2.3 Ventas Acquires Portfolio of Independent Living Communities from Holiday Retirement for US$790 Million 16
2.2.4 BioMarin Pharma Completes Public Offering of Notes for US$750 Million 16
2.2.5 Astellas Pharma Enters Into R&D Agreement with Mitokyne for Drug Discovery 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2013 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2013 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2013 20
3.1.1 Top M&A Deals in October 2013 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2013 - October 2013 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2013 23
3.2.1 Top Equity Offering Deals in October 2013 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2013 - October 2013 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2013 27
3.3.1 Top PE/VC Deals in October 2013 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2013 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2013 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2013-October 2013 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013-October 2013 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2013 - October 2013 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 39
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2013 41
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2013 - October 2013 44
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 45
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 51
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2013 53
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2013 53
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2013 54
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2013 - October 2013 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2013 - October 2013 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 61

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2013 63
6.1.1 Oncology - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2013 67
6.2.1 Central Nervous System - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2013 70
6.3.1 Immunology - Dealsof the Month 72
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2013 73
6.4.1 Infectious Diseases - Deals of the Month 75
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, October 2013 76
6.5.1 Metabolic Disorders - Deal of the Month 78
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2013 81
6.6.1 Cardiovascular - Deal of the Month 82
6.7 Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals, October 2013 84
6.7.1 Hematological Disorders - Deal of the Month 85

7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2013 87
7.1.1 North America - Deals of the Month 89
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2013 91
7.2.1 Europe - Deals of the Month 92
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2013 94
7.3.1 Asia-Pacific - Deals of the Month 96
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2013 97
7.4.1 Rest of the World - Deals of the Month 99

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 100
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2013 - October 2013 100
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2013 - October 2013 102

9 Further Information 104
9.1 Methodology 104
9.2 About GlobalData 105
9.3 Disclosure information 106
9.4 Disclaimer 106

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2013 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2013 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2013 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2013 - October 2013 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2013 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013 - October 2013 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 40
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 41
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 43
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2013 - October 2013 48
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 50
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 52
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2013 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2013 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 56
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2013 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 62
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 64
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 71
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 74
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 77
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 82
Table 38: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 85
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 95
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 98
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 101
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 103

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2013 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2013 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 45
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 49
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 51
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2013 - October 2013 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 60
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 61
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 63
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 67
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 70
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 73
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 76
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 81
Figure 33: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 84
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 94
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 100
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 102

Upcoming Reports:

Wearable Medical Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Over the past decade, the world has been witnessing a great deal of progress in the field of wearable medical technology that has led clinicians to work more efficiently by enabling them extending patient care even outside the hospital environment. The global market for wearable medical technology encompasses continuous glucose monitoring devices, wearable drug delivery devices, wearable patches, sleep monitors, smart watch and smart clothing. These technologies play a critical role in managing and monitoring a variety of chronic diseases ranging from diabetes to cardiovascular...
Concrete Admixtures Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Concrete Admixtures are added to the concrete in the form of fluids or powder, to enhance its strength, durability, chemical resistance and other properties, thus making it more suitable to satisfy the need of modern civil structures. Some of the major factors driving this market are the growing urbanization across the world, increasing demand of infrastructure in developing economies and improving quality of construction. The market for concrete admixtures is on a rise in developing countries. Increasing support from governments and global economic recovery will drive the...
Poland: benzene market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the benzene market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the benzene market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Legal Action Taken by Citic Resources to Recover Missing Materials
Jul 10, 2014  
Citic Resources has filed a claim versus the operator of port warehouse in Qingdao Maritime court. The organization is seeking confirmation that it owns the copper and alumina held at the port, according to a statement released by the organization. The company wants these materials released and delivered to them or seek compensation if these materials are not retrieved. Citic Resources...
IBM to Invest USD 3 Billion in Semiconductor Research
Jul 10, 2014  
Even amidst talks of International Business Machines Corp. (IBM) selling its chip-manufacturing unit, the company has decided to invest USD 3 billion in research and development of semiconductors over the next five years. IBM will fund two research projects to create smaller and more powerful chips that can be used in its systems. The program will also be aimed at developing non-silicon parts...
Chinas Radio, Film, and Television Industry Posts USD 60.1 billion Revenue
Jul 10, 2014  
The radio, film, and television industry in China posted combined revenues of USD 60.1 billion or 373.5 billion yuan for the year 2013. These figures were stated in an official report released in China by the State General Administration of Press, Publication, Radio, Film and Television on Wednesday. While the domestic media industry in China has been on the growth track, heightened...
Malaria Parasites Breed Inside Human Bone Marrow, Says a Recent Study
Jul 10, 2014  
Though it is already known to most of us that malaria parasites attack the bone marrow of humans, escaping the immune system and causing disease, a new research study has found the exact locations where these parasites develop their sanctuaries. This discovery can lead to the research and development of more effective drugs and vaccines against this deadly condition and its...
Brazildecides to Extend Tax Break for Auto Furniture Sales
Jul 10, 2014  
The car and furniture sales in Brazil are safeguarded to its fiscal accounts. It is a six month extension policy where the government would raise tax on the IPI, manufactured goods, or other furniture sales July 1 onwards. According to Finance Minister Guido Mantega, the policy is kept in consideration even for times when sales are down and jobs are skeptical. He informed this to the...